Intevac Announces Fourth Quarter And Full Year 2013 Financial Results
The following excerpt is from the company's SEC filing
The limited amount of capital expenditures in both our hard drive media and solar cell manufacturing markets resulted
in a difficult year for our Equipment business. However, the long-term growth drivers for both of these markets remain positive, commented Wendell Blonigan, president and chief executive officer of Intevac. In our Photonics business, we
completed the final phase of our Apache camera development program and began shipping production units in late December. We expect this program to drive significant Photonics revenue growth in 2014.
Over the course of 2013, the company implemented action
s that reduced operating expenses by 25% and cash burn by more than 50% from the prior year. In
November, we announced a $30 million stock repurchase plan that allows the company to return capital to our stockholders while retaining the flexibility to effectively manage and grow the business. Our market share and technology leadership
position in the hard disk drive media manufacturing market, innovative new equipment products for solar cell manufacturing, a growing Photonics business, reduced operating expenditure levels, and solid balance sheet provide a strong foundation for
Net income for the quarter was $1.7 million, or $0.07 per diluted share, and includes a $3.7 million credit for the change in fair value of certain
contingent consideration obligations related to an acquisition in a prior year. This compares to a net loss of $42.7 million, or $1.82 per share, in the fourth quarter of 2012, which included a $23.4 million valuation allowance established
on certain federal deferred tax assets, $18.4 million in goodwill and intangibles impairment charges, and a $0.7 million credit for the change in fair value of acquisition-related contingent consideration. The non-GAAP net loss was
2.0 million, or $0.08 per share, compared to a non-GAAP net loss $4.2 million or $0.18 per share, for the fourth quarter of 2012.
Revenues were $20.6 million, including $12.8 million of Equipment revenues and Photonics revenues of
$7.7 million. Equipment revenues consisted of one 200 Lean system, upgrades, spares and service. Photonics revenues included $3.5 million of research and development contracts. In the fourth quarter of 2012, revenues were
$17.5 million, including $9.4 million of Equipment revenues and Photonics revenues of $8.1 million, which included $4.9 million of research and development contracts.
Equipment gross margin was 38.1% compared to 46.0% in the fourth quarter of 2012 as a result of a lower mix of higher-margin upgrades. Photonics gross margin
was 36.8% compared to 37.4% in the fourth quarter of 2012, reflecting lower overhead absorption as a result of lower program activity. Consolidated gross margin was 37.6%, compared to 42.0% in the fourth quarter of 2012.
R&D and SG&A expenses were $10.3 million compared to $13.5 million in the fourth quarter of 2012. Total operating expenses were
$6.6 million and were net of a $3.7 million credit for the change in fair value of acquisition-related contingent consideration. Total operating expenses in the fourth quarter of 2012 of $31.2 million included $18.4 million in
non-cash goodwill and intangibles impairment charges offset in part by a $0.7 million credit for the change in fair value of acquisition-related contingent consideration.
Order backlog totaled $59.9 million on December 31, 2013, compared to $70.7 million on September 28, 2013 and $35.2 million
on December 31, 2012. Backlog as of December 31, 2013 includes one 200 Lean system and one Solar system as compared to two 200 Lean systems on September 28, 2013. Backlog as of
December 31, 2012 did not include any 200 Lean systems.
The company ended the year with $81.4 million of cash and investments and
$124.7 million in tangible book value. The company repurchased $1.7 million in stock during the fourth quarter as part of the Stock Repurchase Program announced in November.
The net loss was
$15.7 million, or $0.66 per share, compared to a net loss of $55.3 million, or $2.37 per share, for fiscal 2012. The non-GAAP net loss, which excludes a $3.7 million credit for the change in fair value of acquisition-related
contingent consideration, a $0.7 million restructuring charge and a $0.2 million divestiture loss, was $18.5 million or $0.78 per share. This compares to the 2012 non-GAAP net loss of $16.2 million, or $0.69 per share,
which excludes a $23.4 million valuation allowance established on certain federal deferred tax assets, $18.4 million in goodwill and intangibles impairment charges, a $3.0 million bad debt charge, a $0.2 million credit for the
change in fair value of acquisition-related contingent consideration and a $2.2 million divestiture gain.
Revenues were $69.6 million,
including $39.1 million of Equipment revenues and Photonics revenues of $30.5 million, compared to revenues of $83.4 million, including $52.5 million of Equipment revenues and Photonics revenues of $30.9 million, for 2012.
Equipment gross margin was 31.0%, compared to 44.9% in 2012, primarily due to the lower level of revenue from upgrades, lower factory absorption, a
refurbishment provision for a solar evaluation system, and the lower system margin on the first solar implant ENERGi system recognized for revenue. Photonics gross margin was 32.3% compared to 34.2% in 2012, reflecting lower margins on our
technology development programs. Consolidated gross margin was 31.6%, compared to 40.9% in 2012.
R&D and SG&A expenses were $43.3 million compared to $57.7 million in 2012. Total operating
expenses were $39.6 million, which includes a $3.7 million credit for the change in fair value of acquisition-related contingent consideration, and $0.4 million in severance costs, and were down 49.8% from $78.9 million in the
2012. The operating loss of $17.8 million includes a $3.7 million credit for the change in fair value of acquisition-related contingent consideration, $0.7 million of restructuring charges and a $0.2 million loss on the sale of
our Raman spectroscopy product line. The operating loss of $42.5 million for 2012 included $18.4 million in non-cash goodwill and intangibles impairment charges and a $3.0 million bad debt charge, offset in part by a $2.2 million
gain on the sale of our mainframe technology and a $0.2 million credit for the change in fair value of acquisition-related contingent consideration.
non-GAAP results exclude the impact of the following, where applicable: (1) changes in fair value of contingent consideration liabilities associated with business combinations; (2) restructuring charges; (3) gains or losses on sales
of product lines and technology assets; (4) certain bad debt charges; (5) impairments of goodwill and intangible assets; and (6) deferred tax asset valuation allowance. A reconciliation of the GAAP and non-GAAP results is provided in
the financial tables included in this release.
Management uses non-GAAP results to evaluate the companys operating and financial performance in
light of business objectives and for planning purposes. These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies. Intevac believes these measures enhance investors
ability to review the companys business from the same perspective as the companys management and facilitate comparisons of this periods results with prior periods. The presentation of this additional information should not be
considered a substitute for results prepared in accordance with GAAP.
The company will discuss its financial results and outlook in a conference call today at 1:30 p.m. PST (4:30 p.m. EST). To participate in the
teleconference, please call toll-free (877) 334-0811 prior to the start time. For international callers, the dial-in number is (408) 427-3734. You may also listen live via the Internet at the companys website, www.intevac.com, under
the Investors link, or at www.earnings.com. For those unable to attend, these web sites will host an archive of the call. Additionally, a telephone replay of the call will be available for 48 hours beginning today at 7:30 p.m. EST. You may
access the replay by calling (855) 859-2056 or, for international callers, (404) 537-3406, and providing Replay Passcode 31095997.
In our Equipment business, we are a leader in the design, development and manufacturing of high-productivity process equipment solutions. Our systems are
production-proven for high-volume manufacturing of substrates with precise thin film properties, such as those required in the hard drive and solar cell markets we currently serve.
In the hard drive industry, our 200 Lean® systems process approximately 60% of all magnetic disk
media produced worldwide. In the solar cell manufacturing industry, our high-throughput thin film process equipment enables increased conversion efficiency of silicon solar cells while also reducing manufacturing costs.
In our Photonics business, we are a leader in the development and manufacture of leading-edge, high-sensitivity
imaging products and vision systems. Our products primarily address the defense markets.
The three months and year ended December 31, 2013 include $3.7 million credit for the change in fair value of acquisition-related contingent consideration. The three months and year ended
December 31, 2012 include $0.7 million and $0.2 million credits, respectively for the change in fair value of acquisition-related contingent consideration.
Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010.
Results for the year ended December 31, 2013 include severance and other employee-related costs $742,000 related to the restructuring program announced on February 1, 2013.
The year ended December 31, 2013 includes the loss on sale of the Raman spectroscopy product line of $208,000. On March 29, 2013, the company sold certain assets including tangible and intangible
assets and divested of certain liabilities which comprised its Raman spectroscopy product line for proceeds of not to exceed $1.5 million of which $500,000 was paid in cash upon closing and up to $1.0 million is in the form of an earnout.
Intevac did not recognize the earnout payments upon closing given the uncertainties associated with the achievement of the earnout.
The year ended December 31, 2012 includes the gain on sale of the mainframe technology of $2.2 million. On January 6, 2012, the Company sold certain assets including intellectual property and
residual assets which comprised its semiconductor mainframe technology for proceeds of $3.0 million.
The year ended December 31, 2012 includes a write-off of a promissory note from a customer in the amount of $3.0 million due to the insolvency of the customer.
In accordance with ASC Topic 740, Income Taxes, the company determined based upon an evaluation of all available objectively verifiable evidence, including but not limited to the companys U.S. operations falling
into a cumulative three year loss, that a non-cash valuation allowance should be established against its U.S. deferred tax assets which are comprised of accumulated and unused U.S. tax credits, and net operating losses and other temporary book-tax
differences. The establishment of a non-cash valuation allowance on the companys U.S. deferred tax assets does not have any impact on its cash, nor does such an allowance preclude the company from utilizing its tax losses, tax credits or other
deferred tax assets in future periods.
The amount represents the estimated income tax effect of the non-GAAP adjustments. The company calculated the tax effect of non-GAAP adjustments by applying an applicable estimated jurisdictional tax rate to each
specific non-GAAP item.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Intevac
makes a similar move, sign up!